Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eddingpharm International Holdings Ltd.

www.eddingpharm.com

Latest From Eddingpharm International Holdings Ltd.

Amarin Will Double Vascepa Sales Team In Big Bet On Supplemental Approval

Anticipating a label expansion this fall based on the REDUCE-IT cardiovascular outcomes study, Amarin will double its sales force and has raised revenue guidance. Approved to reduce very high triglyceride levels, Vascepa sales total $170m-$174m so far this year.

Life Cycle Management Business Strategies

Asia Deal Watch: Oxford Biomedica’s First Japanese Partnership Focuses On Rare Retinal Disorder

Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.

Deals Asia Pacific

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

China Business Strategies

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Eddingpharm (Cayman) Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Hong Kong
  • Parent & Subsidiaries
  • Eddingpharm International Holdings Ltd.
  • Senior Management
  • Xin Ni, Chmn. & CEO
    Guili Miao, CFO
  • Contact Info
  • Eddingpharm International Holdings Ltd.
    Phone: (852) 37550555
    Ste. 3306, 33rd Fl., Tower 6
    The Gateway Harbor City,
    Hong Kong
Advertisement
Advertisement
UsernamePublicRestriction

Register